Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA to direct adjuvant immunotherapy across mismatch repair-deficient solid tumors

In this prospective phase II study, 184 patients with resected early-stage dMMR solid tumors were screened for postoperative MRD with tumor-informed ctDNA testing. Thirteen MRD-positive patients received 6 months of pembrolizumab; ctDNA clearance at 6 months was achieved in 11 of 13 (85%), and 5 treated patients (38%) later developed recurrence during a median follow-up of 59 months (95% CI: 52-NR). Among 152 MRD-negative patients managed with observation, 14 (9%) developed recurrence, and 2-year recurrence-free survival was 92%.

Annals of OncologyPubMed 43025593DOI 10.1016/j.annonc.2026.11.005